Displaying 671 (all) recruiting clinical trials.
-
The DISCOVER INOCA Prospective Multi-center Registry - Determining the Cause of Coronary Vasomotor Disorders in Patients with Ischemia and No Obstructive Coronary Artery Disease
This is a prospective, multicenter, registry of stable patients with ischemia and no obstructive coronary artery disease (INOCA) evaluated by coronary angiography, intravascular imaging, and ...Phase N/A
Non-Interventional
-
Cerliponase alfa Observational Study
This is a, multicenter, observational study for patients with a confirmed diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as TPP1 deficiency ...Phase N/A Non-Interventional
-
Distal Ischemic Stroke Treatment with Adjustable Low-profile Stentriever
Evaluate the safety and effectiveness of the treatment with the investigational Tigertriever 13 device as compared to standard medical management.Phase N/A
Interventional
-
A multi-cohort randomized Phase 2 open-label study to assess the preliminary efficacy safety and pharmacokinetics of BIVV020 for prevention and treatment of antibody-mediated rejection in adult kidney transplant recipients.
Antibody-mediated rejection (AMR) remains as the most common cause of allograft failure following kidney transplantation (1, 2). The primary mechanism of AMR involves activation of ...Phase
Interventional
-
Screening Assessment of Overlap Spondyloarthritis in Patients with Inflammatory Bowel Disease
Despite the known prevalence of SpA in patients with IBD, a formalized screening and disease activity monitoring strategy is not routine standard of care. This ...Phase N/A Non-Interventional
-
A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (POETYK-SLE-2)
The 52-week double-blinded study is divided into 3 separate periods that will take about 60 weeks to complete: • Screening Period (4 weeks), • Treatment Period (52 ...Phase
Interventional
-
A Phase 1/2 Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination with an anti-PD-1 Antibody in Patients with STK11-Mutated Advanced Solid Tumors
This is a first-in-human Phase 1/2, open-label, multicenter, dose-escalation and -expansion study designed to determine the MTD of TNG260 as single agent and in ...Phase
Interventional
-
A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
The purpose of this first-in-human (FIH) study is to investigate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), maximum tolerated dose (MTD), recommended Phase 2 dose ...Phase
Interventional
-
A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma ...Phase
Interventional
-
A Single-Arm Phase 2 Study Of Daratumumab In Previously Treated Stk11/Lkb1 Mutated Non-Small Cell Lung Cancer
This is a single arm, signal finding study of daratumumab in metastatic NSCLC patients with an STK11/LKB1 mutation. Patients will have received previous standard ...Phase
Interventional
